BiondVax Pharmaceuticals begins testing of universal flu vaccine
Company officials with BiondVax Pharmaceuticals, whose CSO, Dr Tamar Ben-Yedidia, will be speaking at the World Vaccine Congress Washington, announced that it is beginning a Phase II-A clinical trial for its Multimeric-001 universal flu vaccine.
BiondVax president and CEO Dr. Ron. Babecoff told Globes.co.il that the company will soon begin giving trial participants initial shots of the vaccines. The results of these trials, he said, should be published by the second quarter of 2011.
“Beginning this trial is a significant milestone in the clinical development of the Multimeric-001 universal flu vaccine, which is considered the first of its kind in the world,” Babecoff told Globes.co.il. “After the success of the two previous trials, in which the Multimeric-001 vaccination proved its safety and arousal of a reaction in older and younger people, the new trial is an important stage in developing the universal flu vaccine. This important trial will take us a significant step forward in realizing the company’s vision of ensuring protection against flu through a single vaccination that will replace the need to be vaccinated each year as existing vaccines require today.”
Dr Tamar Ben-Yedidia, Chief Scientific Officer at BiondVax will be joining Dr Melissa Malhame, Senior Director Dynavax, Dr Alfredo Nicosia, Chief Scientific Officer, Okairos and Dr Carlton Brown, Chief Executive Officer, ITS Innovation, on the panel session: “Universal influenza vaccine: what challenges must be overcome to ensure feasibility?” at the 11th annual World Vaccine Congress Washington.